Use of medium-chain length fatty acids such as capric acid, caprylic acid orlauric acid and their salts or mono- ordi- or triglycerides as nephroprotection agents to protect against renalfailure progression in chronic kidney diseases This includesthe treatment of kidney diseases associated with nephrectomy, renal fibrosis,glomerular scelrosis and end-stage renal disease Alsoincludes the protection of the kidney against cytotoxic agent used inchemotherapy or autoimmune diseases or transplantation Furtherincludes the treatment of renal failure progression associated withhypertension, infarct, tumour, diabetes mellitus, autoimmunity orinflammation.
